Last reviewed · How we verify

NCT03383315

Role of Prophylactic Metoclopramide With Tramadol in Trauma Patients

Completed Phase 2 Last updated 26 December 2017
What this trial tests

Phase 2 trial testing Tramadol in Trauma in 191 participants. Completed in 30 September 2017.

Timeline
1 July 2017
Primary endpoint
30 September 2017
30 September 2017

Quick facts

Lead sponsorUniversity of Malaya
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposeprevention
Enrollment191
Start date1 July 2017
Primary completion30 September 2017
Estimated completion30 September 2017
Sites1 location across Malaysia

Drugs / interventions tested

Conditions studied

Sponsor

University of Malaya

Who can join

18 and older, any sex, with Trauma or Opioid Analgesic Adverse Reaction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Tramadol is widely used as analgesic in trauma patients. However, it causes side effects, most notably nausea and vomiting. This study aim to determine the role of prophylactic metoclopramide in preventing tramadol induced nausea and vomiting.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Tramadol

Trials testing the same drug.

Other recruiting trials for Trauma

Currently open trials in the same condition.

Other University of Malaya trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03383315.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing